| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Aug 17, 2023
Coeptis bolsters pipeline with two Phase 1 clinical stage assets leveraging NK cell therapies in relapsed or refractory acute myeloid leukemia (AML)/high risk MDS and hospitalized respiratory...
-
Aug 1, 2023
513(g) request will help initiate dialogue with FDA and guide regulatory pathway WEXFORD, Pa., Aug. 1, 2023 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or "the...
-
Jun 16, 2023
Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or the "Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced the closing of...
-
Jun 14, 2023
Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or the "Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced the pricing of...
-
Jun 9, 2023
Trading to commence effective with the open of business on June 13, 2023 WEXFORD, Pa. , June 9, 2023 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or the...